( NASDAQ-SMALL:ONCS )

News from OncoSec Medical Incorporated A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 03, 2017, 06:01 ET OncoSec to Present at Investment Conferences in January

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Dec 08, 2016, 16:01 ET OncoSec Announces First Quarter Financial Results for Fiscal Year 2017

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced...


Dec 01, 2016, 06:01 ET OncoSec to Present at the 9th Annual LD Micro Main Event

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Nov 17, 2016, 06:01 ET OncoSec Announces Key Corporate Initiatives at Inaugural Investor & Analyst Day on November 17, 2016

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will provide updates...


Nov 15, 2016, 06:01 ET OncoSec to Host First Quarter Financial Results Conference Call on December 8, 2016

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that...


Nov 11, 2016, 13:01 ET OncoSec Presents Positive Interim Response Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2016

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented new...


Nov 08, 2016, 08:01 ET OncoSec Announces Positive Interim Response Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2016

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Nov 01, 2016, 06:01 ET OncoSec to Present at Scientific and Investment Conferences and to Host Inaugural Investor and Analyst Day in November

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Oct 18, 2016, 06:01 ET OncoSec to Host Investor & Analyst Day on November 17, 2016 Spotlighting Industry-Leading Intratumoral Immunotherapy Pipeline and Next Generation Research and Device Development

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Oct 13, 2016, 16:01 ET OncoSec Announces Fourth Quarter and Year End Results for Fiscal Year 2016

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced...


Oct 13, 2016, 06:01 ET OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2016

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that...


Oct 10, 2016, 06:00 ET OncoSec to Present at Scientific and Investment Conferences in October

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that...


Sep 30, 2016, 06:01 ET OncoSec to Host Fourth Quarter and Fiscal Year End Financial Results Conference Call on October 13, 2016

 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced...


Sep 06, 2016, 06:00 ET OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer

 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced...


Sep 01, 2016, 06:00 ET OncoSec to Present at Scientific and Investment Conferences in September

 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today...


Aug 15, 2016, 16:01 ET OncoSec Announces Peer-Reviewed Publication of T-Cell Exhaustion Marker to Predict Response to Anti-PD-1 Therapy in Melanoma

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the...


Jun 28, 2016, 06:00 ET OncoSec Presents Significant Advancements in Electroporation Technology for Immunotherapy

 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, presented recent...


Jun 16, 2016, 10:15 ET OncoSec Presents Preliminary Findings from Head and Neck Phase II Clinical Trial at EUROGIN 2016 Conference

 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented...


Jun 09, 2016, 16:01 ET OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2016

 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced...


Jun 06, 2016, 06:00 ET OncoSec Collaborators Present Results of Novel T-Cell Exhaustion Marker to Predict Response to Anti-PD-1 Monotherapy

 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced...


Jun 01, 2016, 06:00 ET OncoSec to Present at Scientific and Investment Conferences in June

 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today...


May 23, 2016, 06:00 ET OncoSec Announces $10 Million At-The-Market Registered Direct Offering

 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today...


May 18, 2016, 06:00 ET OncoSec to Host Third Quarter Financial Results Conference Call on June 9, 2016

OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that...


Apr 19, 2016, 16:45 ET OncoSec Presents Positive Melanoma Clinical Data at American Association for Cancer Research (AACR) Annual Meeting 2016

 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented...


Apr 13, 2016, 06:00 ET OncoSec to Host Webcast and Panel Discussion on New Melanoma Clinical Data

 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will host a...